Bausch+Lomb announced today that an affiliate acquired Elios Vision,developer of a minimally invasive glaucoma surgery(MIGS)procedure.

博士伦公司今天宣布，其子公司收购了微创青光眼手术（MIGS）开发商Elios Vision公司。

The Elios procedure uses an excimer laser to treat glaucoma in conjunction with cataract surgery without implants.Bausch+Lomb believes the deal enhances its glaucoma portfolio which already features pharmaceutical and surgical approaches.

Elios手术使用准分子激光治疗青光眼，同时进行白内障手术，无需植入人工晶体。博士伦认为，这项交易增强了其青光眼产品组合，该产品组合已包括药物和手术方法。

Compared to other glaucoma surgery techniques,MIGS offers a safe and effective approach to lowering intraocular pressure.It also features a faster recovery time,according to a news release.Elios’version offers a tissue-friendly,precision,non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma.The company currently offers the CE-marked technology in Europe and is pursuing FDA approval.

与其他青光眼手术技术相比，MIGS是一种安全有效的降低眼压的方法。据一份新闻稿称，它还具有恢复时间更短的特点。Elios公司的版本为青光眼治疗提供了一种组织友好、精确、基于非热激光且高度可采用的手术方法。该公司目前在欧洲提供获得CE认证的技术，并正在申请美国食品和药物管理局的批准。

Former Elios Chair and CEO Elliot Friedman said the companies aim to make combining cataract and glaucoma treatment the new standard of care.Friedman said the global presence of Bausch+Lomb makes that“even more attainable.”

艾里奥斯公司前董事长兼首席执行官埃利奥特-弗里德曼（Elliot Friedman）说，两家公司的目标是使白内障和青光眼的联合治疗成为新的治疗标准。弗里德曼说，博士伦的全球业务使这一目标“更容易实现”。

“Today’s announcement further demonstrates our commitment to investing in smart,innovative technologies that enable eye care professionals to better address the evolving needs of their patients,”said Luc Bonnefoy,president,Surgical,Bausch+Lomb.“The ELIOS system offers a differentiated approach for the treatment of glaucoma,a condition expected to increase in prevalence by 47%from 2020 to 2040.”

“博士伦公司手术部总裁Luc Bonnefoy说："今天的声明进一步证明了我们投资于智能创新技术的承诺，这些技术使眼科护理专业人员能够更好地满足患者不断变化的需求。“ELIOS系统为治疗青光眼提供了一种与众不同的方法，预计从2020年到2040年，青光眼的发病率将增加47%。